In fact, companies have invested over $20 billion in research into such drugs since the 1990s. The reason why is clear: the market lifestyle ... cessation and had sales of $174m in 2000.

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

“Despite the allure of the lucrative orphan drug market, this is not a viable sector ... The collective sales data from these therapies with organ drug designations reveal that Roche has ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Astrazeneca's share price fall was triggered by ongoing investigations in China and disappointing trial data for its cancer ...

Analysts were looking for Mounjaro sales of $4.20 billion and $1.69 billion for Zepbound for the quarter, according to LSEG data ... diabetes drugs. It's just "a consequence of a market that's ...

On Tuesday, a tiny shred of data on ... billion in market value. The data, spotted by an analyst at Cantor Fitzgerald, focused on concerns about potential side effects with the drug, called ...

by pushing its newer immunology drugs Skyrizi and Rinvoq amid competition from multiple less-expensive biosimilars that hit the U.S. market last year. While Humira's sales volumes have ...

due to big misses in sales of anti-obesity drugs Mounjaro and Zepbound. The company said sales of Mounjaro and Zepbound were hurt in the latest quarter by wholesalers cutting inventory ...

Lilly said inventory decreases by wholesale distributors hurt sales of its diabetes drug Mounjaro and anti-obesity medicine Zepbound. Mounjaro sales more than doubled to $3.11 billion last quarter ...